Compare Abbott Laboratories (ABT) vs Vale SA (VALE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Vale SA — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Vale SA trades at $14.03 (market cap $62.60B). The key difference: Abbott Laboratories is far larger — about 2.7× Vale SA's market cap, and Vale SA pays the higher dividend (8.57%). Which is the better fit depends on your goals.
| ABT | VALE | |
|---|---|---|
Market Cap | $166.94B | $62.60B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $17.82 |
52-Week Low | $82.57 | $9.53 |
Enterprise Value | $193.69B | $79.52B |
Dividend Yield | 2.63% | 8.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VALE trades at $14.69, down 2.0% over the past day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q3 2025 but missing in Q4 2025 and Q1 2026. Revenue for 2025 was $38.40 billion with a net income margin of 7.21%, while cash flow from operations remained strong at $8.80 billion. Recent news includes a board governance dispute and a $2.56 billion decarbonization investment plan announced on June 15, 2026 (Reuters).
The outlook is cautious with a consensus analyst price target of $18.30, implying potential upside, but risks include volatile iron ore prices, rising debt-to-asset ratios, and execution challenges. Earnings growth and cost management are key catalysts for stock performance amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
